Sign inTry free

Annovis Bio (ANVS) stock

Brain disease drugs , market cap $49.9M

$1.21
+2.54%

Pre-market. Prices 17 minutes old, as of 6:01 AM ET. Pro members see real-⁠time prices.

Quality Score
-7
Poor
In its industry
#285of 308
Biotech

ANVS's Quality Score was unchanged on Wed, Oct 7, at -7.

Since its Nov 2021 high: down 97%, a $14.5M loss → a $49.5M loss a year. 5 more reasons behind ANVS's -7, for Pro members.

NextOct 2026“Start: The AD OLE study is expected to initiate in October 2026.”Trial start · 8-K, Aug 14
Cash$18.7M, about 1 quarter at the last year's spendingOn Jun 30 · the company says “into the third quarter of 2026”

Follow ANVS's trial news. Pro members can get an alert when Annovis Bio files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when ANVS files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why ANVS is down

Down 38% in 3 months, 20% under its 50-day average.

Down more than its industry: the 299 other stocks in it fell a median 18% over the same 3 months.

−3Long-term trend below a falling 200-day average, down over one year, down over two years

What's next

Wed Oct 14: Special meeting, online10:00 AM ET. Proxy filed Sep 11.

Expected to report Wed Nov 11, after the close

After its last 4 reports it closed -3.9% on average, higher 0 of 4 times.

For Pro members

  • 5 more things pulling ANVS's score down
  • What would turn ANVS's score around: 8 things
Cash$18.7M, about 1 quarter at the last year's spendingOn Jun 30 · the company says “into the third quarter of 2026”

What's next for ANVS, and how long its cash lasts

From Annovis Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Oct 2026“Start: The AD OLE study is expected to initiate in October 2026.”Trial start · 8-K, Aug 14

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADPhase 3 · Active · 760 people · main data estimated Dec 2027 · NCT06709014

2 more trials, 3 more milestones and 53 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 1 quarter

$18.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into the third quarter of 2026” (8-K, Mar 16).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Feb 1, 2024)
  • At-the-market share sales program (424B5, filed Dec 11, 2024)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 11 raises and their amounts, and the share count against a year ago.

Insiders

Director Michael B Hoffman bought 76,344 shares on May 20. 1 more insider trade this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Maria-Luisa Maccecchini buys or sells

For Pro members: every trade, and Maria-Luisa Maccecchini’s 8 filings and quotes.

Get an optional alert when ANVS files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 110 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ANVS and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

ANVS has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on ANVS, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1441.2

    Above 30, below 50.

  • MACD (12, 26, 9)Above signal

    Crossed above its signal line 10 sessions ago.

  • 50-day average$1.52

    The price is 20.4% below it.

  • 200-day average$2.13

    The price is 43.2% below it. The 50-day is below the 200-day, since Mar 19.

  • ADX 1426.3

    25 or more, with +DI below -DI.

  • Support$1.04

    Swing low from Sep 16, 14.0% below the price.

  • Resistance$1.43

    Swing high from Sep 28, 18.2% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $1.04 to $1.37.

  • Volume0.4x

    Against its 20-day average, for the time of day.

How ANVS ranks in Biotech

ANVS is #285 of 308 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does ANVS report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 34 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 14, 2026After close-1.6%-6.0%-1.6%
May 15, 2026After close+1.5%-0.5%+8.3%
Mar 16, 2026After close+0.7%-3.2%-11.7%
Nov 12, 2025After close-2.1%-5.8%+39.1%

The gap is the next open against the close before the report; the reaction is where that session closed. ANVS closed higher after 0 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

ANVS's officers and directors

Officers and directors with a Form 4 here in the last 12 months. Open one for their trades at every company.

See insider trades by person

About Annovis Bio

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

7 employeesMalvern, PAannovisbio.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of ANVS's score, with the points and the reason
  • All 14 checks on ANVS and on all 3,283 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on ANVS
See all 14 checks on ANVSSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders, and profits come straight from the SEC. That means Form 4 filings, 13F filings, and XBRL financial data on EDGAR. Where a company's SEC figures leave the Quality Score's sales, share count, or cash flow line empty, the score reads that figure from Massive's statements, and the Score tab says so. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch, and Yahoo Finance publish, shown as the headline, the source, and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.